Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe changes appear to be cosmetic: the page's layout/formatting has been updated, but there is no visible modification to core study details such as title, objectives, design, outcomes, eligibility criteria, enrollment, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check39 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference4%

- Check46 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check61 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' navigation item has been removed. No substantive content changes were detected.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%

- Check75 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several terms related to diseases and previous location details have been removed.SummaryDifference2%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.